Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent
McGovren, J.P.; Neil, G.L.; Denlinger, R.H.; Hall, T.L.; Crampton, S.L.; Swenberg, J.A.
Cancer Research 39(12): 4849-4855
1979
ISSN/ISBN: 0008-5472 PMID: 498112 Document Number: 147790
Document emailed within 1 workday
Related Documents
Egorin, M.J.; Clawson, R.E.; Cohen, J.L.; Ross, L.A.; Bachur, N.R. 1979: Cellular pharmacology of 7(R)-O-methylnogarol: a new anticancer agent Journal of Pharmacology and Experimental Therapeutics 210(2): 229-236Wojtukiewicz, M.Z.; Omyła, J.; Kozłowski, L.; Szynaka, B. 2000: Cardiotoxicity of anthracycline Postepy Higieny i Medycyny Doswiadczalnej 54(4): 467-485
Lipshultz, S.E.; Sanders, S.P.; Goorin, A.M.; Krischer, J.P.; Sallan, S.E.; Colan, S.D. 1994: Monitoring for anthracycline cardiotoxicity Pediatrics 93(3): 433-437
Rivero, O.; Mordeglia, F. 1987: Epirubicin: an anthracycline of minor cardiotoxicity Medicina 47(3): 320-321
2008: Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients Prescrire international 17(97): 195
McGuire, W.P. 1978: Prospective monitoring for anthracycline cardiotoxicity: an introduction Cancer Treatment Reports 62(6): 855
De Leonardis, V.; De Scalzi, M.; Neri, B.; Bartalucci, S.; Cinelli, P. 1987: Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens International Journal of Clinical Pharmacology Research 7(4): 307-311
Orditura, M.; De Vita, F.; Ciaramella, F.; Catalano, G. 1994: Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 9(4): 243-248
Okada, Y.; Horikawa, K.; Sano, M. 1997: Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(5): 585-589
Ferrans, V.J. 1978: Overview of cardiac pathology in relation to anthracycline cardiotoxicity Cancer Treatment Reports 62(6): 955-961
Ali, A.A.S.; Al-Mudhafar, A.M.J. 2011: Prediction of anthracycline induced cardiotoxicity: study of thirty-one Iraqi adult patients Gulf Journal of Oncology 10: 33-39
Lemez, P.; Maresová, J. 1996: Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias Neoplasma 43(6): 417-419
Liu, L.; Liu, Z-zhe.; Liu, Y-ye.; Zheng, Z-dong.; Liang, X-feng.; Han, Y-ling.; Xie, X-dong. 2013: Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer Zhonghua Zhong Liu Za Zhi 35(12): 936-940
Inaba, M.; Nagashima, K.; Sakurai, Y.; Fukui, M.; Yanagi, Y. 1984: Reversal of multidrug resistance by non-antitumor anthracycline analogs Gan 75(12): 1049-1052
Povarov, L.S. 1977: Antitumor antibiotics of the anthracycline series and their semisynthetic derivatives Antibiotiki 22(7): 653-667
Inaba, M.; Nagashima, K.; Sakurai, Y.; Fukui, M.; Yanagi, Y. 1984: Reversal of multidrug resistance by non-antitumor anthracycline analogs Gan 75(12): 1049-1052
Eastland, G.W.; Yang, G.; Thompson, T. 1983: Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice Methods and Findings in Experimental and Clinical Pharmacology 5(7): 435-438
Bellelli, A.; Giomini, M.; Giuliani, A.M.; Giustini, M.; Lorenzon, I.; Rusconi, V.; Sezzi, M.L.; Trotta, E.; Belleli, L. 1988: Antitumor effect and cardiotoxicity of a doxorubicin-lecithin association Anticancer Research 8(1): 177-186
Duvernay, V.H.; Eubanks, D.; Perales, R.; Prestayko, A.W.; Crooke, S.T. 1982: The antitumor effects of anthracyclines. II. The stereospecificity of the carbomethoxy group at position 10 of the class II anthracycline molecule Molecular Pharmacology 21(1): 196-203
Serafino, A.; Sinibaldi-Vallebona, P.; Pierimarchi, P.; Bernard, P.; Gaudiano, G.; Massa, C.; Rasi, G.; Ranagnan, G. 1999: Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering? Anticancer Research 19(3a): 1909-1918